Targeting dormant bacilli to fight tuberculosis

Mediterranean Journal of Hematology and Infectious Diseases
Lanfranco FattoriniFederico Giannoni

Abstract

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mtb), which kills about 2 million people annually. Furthermore, 2 billion people worldwide are latently infected with this organism, with 10% of them reactivating to active TB due to re-growth of nonreplicating (dormant) Mtb residing in their tissues. Because of the huge reservoir of latent TB it is important to find novel drugs/drug combinations killing dormant bacilli (microaerophiles, anaerobes and drug-tolerant persisters) surviving for decades in a wide spectrum of granulomatous lesions in the lungs of TB patients. Antibiotic treatment of drug-susceptible TB requires administration of isoniazid, rifampin, pyrazinamide, ethambutol for 2 months, followed by isoniazid and rifampin for 4 months. To avoid reactivation of dormant Mtb to active pulmonary TB, up to 9 months of treatment with isoniazid is required. Therefore, a strategy to eliminate dormant bacilli needs to be developed to shorten therapy of active and latent TB and reduce the reservoir of people with latent TB. Finding drugs with high rate of penetration into the caseous granulomas and understanding the biology of dormant bacilli and in particular of persister cells, phenotypically re...Continue Reading

References

Jan 19, 2016·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Santhi Devasundaram, Alamelu Raja
Jun 12, 2014·Frontiers in Microbiology·Laam LiSebastien P Faucher
Feb 27, 2016·Molecular Microbiology·Kirsten FamullaHeike Brötz-Oesterhelt
Mar 29, 2014·The Lancet Infectious Diseases·Alimuddin I ZumlaAndrew J Nunn
Apr 8, 2017·Pharmaceutical Biology·Vivek Kumar GuptaAnupam Kaushik
Mar 24, 2017·FEMS Microbiology Reviews·Bram Van den BerghJan Michiels
Oct 16, 2019·Antimicrobial Agents and Chemotherapy·Samantha DonnellanGiancarlo A Biagini
Sep 29, 2020·Frontiers in Cellular and Infection Microbiology·Caroline G G BeltranGerhard Walzl
Jun 17, 2015·The Nurse Practitioner·Stephen A Ferrara, Robert E Burke
Jan 30, 2015·The Journal of Biological Chemistry·Irina A RodionovaAndrei L Osterman

Related Concepts

Ethambutol
Lung
Tuberculosis
Antibiotic throat preparations
Bulla
Tuberculosis, Meningeal
Antifungal Antibiotics, Topical
Etiology
Antibiotics, Gynecological
Organism

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.